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rates	 of	 stillbirth	 and	 PDNM	 were	 calculated.	 Multilevel	 logistic	 regression	 models	
examined	the	association	of	stillbirth	and	PDNM	with	selected	risks,	and	the	associa‐
tion	of	mother’s	QoL	at	discharge	after	stillbirth	or	PDNM.
Results:	 For	 women	 with	 PPH,	 the	 rate	 of	 stillbirths	 was	 104.42	 per	 1000	 births	
(n=1978)	and	the	rate	of	PDNM	was	15.56	per	1000	live	births	(n=264).	Cesarean	deliv‐
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1  | INTRODUCTION
Every	 year	 there	 are	 approximately	 0.29	 million	 maternal	 deaths,	
2.6million	stillbirths,	and	2.5	million	neonatal	deaths	worldwide,	 the	
vast	 majority	 of	 which	 occur	 in	 low‐	 and	 middle‐income	 countries	
(LMICs).1–3	Maternal	 and	 newborn	 health	 and	 outcomes	 are	 intrin‐
sically	 linked,4	 with	 maternal	 risk	 factors	 often	 factoring	 in	 poor	
perinatal	 outcomes.	 Postpartum	 hemorrhage	 (PPH)	 is	 the	 largest	
cause	 of	maternal	 deaths	worldwide,	 contributing	 to	 approximately	
20%	of	all	maternal	deaths.5,6	Hemorrhage,	like	other	obstetric	com‐
plications,	 often	occurs	 alongside	 stillbirth	 and	neonatal	 death,7	yet	
there	 has	 been	 limited	 research	 into	 this	 association,	 particularly	 in	
LMICs.	Many	trials	investigating	interventions	only	focus	on	maternal	
outcomes.8	From	the	woman’s	perspective,	the	health	and	well‐being	
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Data	were	 collected	 on	 the	 infant	 outcomes	 to	 assess	 safety	 in	
breastfed	infants	as	TXA	can	pass	via	breastmilk	in	low	quantities,	and	
on	 the	mother’s	 quality	 of	 life	 (QoL)	 for	 the	 purpose	 of	 cost‐effec‐
tiveness	analyses.10	The	 impact	of	perinatal	deaths	on	mothers	was	






is	 associated	 with	 lower	 reported	 QoL	 for	 women	 at	 discharge	 or	
42	days	postpartum	if	still	in	hospital.
2  | MATERIALS AND METHODS
The	present	study	is	a	secondary	analysis	of	data	from	the	WOMAN	
trial,	 which	 has	 been	 detailed	 elsewhere.10,11	 The	 investigators	
recruited	women	 aged	 16	 years	 or	 older	with	 PPH	 after	 a	 vaginal	
birth	or	cesarean	delivery.11	They	defined	PPH	as	“clinically	estimated	
blood	 loss	 of	more	 than	500ml	 after	 vaginal	 birth	 or	 1000ml	 after	
cesarean	section	or	any	blood	loss	sufficient	to	compromise	hemo‐








tum.	 Stillbirth	 was	 defined	 by	 the	 clinician	 as	 birth	 weight,	 length,	
and	gestational	age	were	not	 recorded.	The	stillbirth	 rate	 (SBR)	was	
defined	as	the	number	of	stillbirths	per	1000	births.	If	the	infant	was	
born	alive	but	died	before	discharge	this	was	classified	as	PDNM.	The	
PDNM	 rate	 (PDNMR)	was	 defined	 as	 the	 number	 of	 pre‐discharge	
neonatal	deaths	per	1000	 live	births.	The	QoL	variables	collected	 in	
the	trial	were	from	the	EQ‐5D	scale,	which	measures	problems	with	
















random‐intercept	 logistic	 regression	 models	 were	 used	 to	 account	


























(95%	CI	 326.00–419.25)	 and	 97.85	 (95%	CI	 72.71–130.46)	 among	
mothers	who	 survived.	Figure	2A	 shows	 the	SBRs	 in	 countries	 that	







20.96).	The	PDNMR	among	women	who	 died	was	 62.93	 per	 1000	
F I G U R E  1  Flowchart	of	WOMAN	trial	and	restriction	to	singleton	births	for	this	analysis.	Our	analyses	use	data	from	the	WOMAN	trial	
which	trialled	tranexamic	acid	in	PPH,11	restricted	to	singleton	deliveries.
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Our analyses use data from the WOMAN trial which trialled tranexamic acid in PPH,11 restricted to 
singleton deliveries.
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Country (median days to discharge amongst women who survived, interquartile range)








Overall,	 50.91%	 of	 women	 who	 had	 a	 stillbirth	 were	 reported	
to	have	a	problem	with	QoL	overall	compared	to	36.53%	of	women	
who	had	a	live	birth.	Of	the	women	who	had	a	pre‐discharge	neonatal	


























being	 anxious	 or	 depressed	 (OR	5.56,	 95%	CI	 4.83–6.41;	OR	5.08,	
95%	CI	3.60–7.17,	respectively).
There	 is	 mixed	 evidence	 that	 additional	 maternal	 complications	






and	 pre‐discharge	 neonatal	 deaths	 (n=264)	 in	 the	 WOMAN	 trial,	
which	 had	 not	 previously	 been	 reported,	 alongside	 the	 455	mater‐
nal	deaths.	 Indeed,	 there	are	1787	more	fetal/neonatal	deaths	than	
maternal	 deaths	 in	 this	 trial.	 The	 present	 review	 of	 the	 literature	













rates.	Maternal	 conditions	 such	 as	 pre‐eclampsia	 or	 other	 placental	
conditions	lead	to	increased	risks	of	both	PPH	and	perinatal	mortal‐






























adverse	 maternal	 outcomes	 (additional	 complications	 and	 maternal	
F I G U R E  2   (A)	Stillbirth	rates	(95%	CI)	for	countries	in	the	WOMAN	trial	contributing	at	least	500	patients,	adjusted	for	clustering	by	site.	
(B)	Pre‐discharge	neonatal	mortality	rates	(95%	CI)	in	countries	in	the	WOMAN	trial	that	contributed	more	than	500	patients,	adjusted	for	
clustering	by	site.
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T A B L E  1  Adjusted	ORs	from	multilevel	logistic	regression	modeling	for	18 942	women	with	PPH	in	the	WOMAN	trial	regarding	selected	
risk	factors.
Risk factors n (%) Crude OR (95% CI); P value b  Adjusted ORc  (95% CI); P valued , (included confounders)
Stillbirth 1978	(10.44)
Maternal	age	(years) P<0.0001 P<0.0001	(n=18 935)
<20 59	(6.13) 1.00 1.00
20–24 341	(8.51) 1.42	(1.07–1.89) 1.52	(1.14–2.04)
25–29 585	(10.04) 1.71	(1.29–2.25) 1.77	(1.33–2.35)
30–34 529	(10.82) 1.86	(1.41–2.46) 1.87	(1.40–2.49)
35–39 343	(13.19) 2.32	(1.74–3.10) 2.21	(1.64–2.97)
40+ 121	(18.64) 3.51	(2.51–4.91) 3.65	(2.59–5.14)
Mode	of	delivery P<0.0001 P=0.0001	(MA,	DL,	AMC,	MD)	(n=18 934)
Vaginal 1330	(9.86) 1.00 1.00
Cesarean 648	(11.87) 1.23	(1.11–1.36) 1.16	(1.03–1.30)
Estimated	blood	loss	(mL) P<0.0001e  P<0.0001	(MA,	DL,	MoD)	(n=18 933)
≤500 30	(5.14) 1.00 1.00
501–1000 624	(6.70) 1.33	(0.91–1.93) 1.15	(0.78–1.70)
1001–1500 588	(11.03) 2.29	(1.57–3.34) 2.00	(1.34–2.96)
>1500 736	(19.87) 4.58–3.13–6.69) 4.03	(2.71–5.99)
Maternal	complications P<0.0001 P<0.0001	(MA,	DL,	MoD)	(n=18 934)
Yes 253	(33.86) 4.89	(4.17–5.75) 4.37	(4.68–5.19)
Maternal	death P<0.0001 P<0.0001	(MA,	DL,	MoD)	(n=18 935)
Yes 169	(37.14) 5.44	(4.47–6.64) 4.43	(3.59–5.45)
PDNM 264 (1.56)
Maternal	age	(years) P<0.0001e  P=0.12	(n=16 957)
<20 9	(1.00) 1.00 1.00
20–24 46	(1.25) 1.26	(0.62–2.59) 1.39	(0.66–2.92)
25–29 67	(1.28) 1.29	(0.64–2.59) 1.32	(0.64–2.73)
30–34 77	(1.77) 1.79	(0.89–3.58) 1.73	(0.84–3.58)
35–39 52	(2.30) 2.34	(1.15–4.78) 2.01	(0.96–4.23)
40+ 13	(2.46) 2.51	(1.06–5.92) 2.18	(0.89–5.33)
Mode	of	delivery P=0.0001 P=0.14	(MA,	EBL,	AMC,	MD)	(n=16 954)
Vaginal 160	(1.32) 1.00 1.00
Cesarean 104	(2.16) 1.66	(1.29–2.13) 1.27	(0.93–1.75)
Estimated	blood	loss	(mL) P<0.0001e  P<0.0001	(MA,	DL,	MoD)	(n=16 955)
≤500 2	(0.36) 1.00 1.00
501–1000 82	(0.94) 2.63	(0.64–10.71) 1.94	(0.47–8.07)
1001–1500 83	(1.75) 4.91	(1.20–20.05) 3.12	(0.74–13.11)
>1500 97	(3.27) 9.32	(2.29–38.05) 5.74	(1.36–24.25)
Maternal	complications P<0.0001 P<0.0001	(MA,	DL,	MoD)	(n=16 956)
Yes 37	(7.40) 5.72	(3.98–8.2) 3.85	(2.55–5.82)
Maternal	death P<0.0001 P=0.0002	(MA,	DL,	MoD)	(n=16 957)
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death)	 and	 stillbirth	 and	 PDNM.	 The	 strength	 of	 the	 association	 is	
clear	and	while	stillbirth	would	have	occurred	before	the	hemorrhage,	
and	the	neonatal	death	may	occur	after,	all	these	outcomes	are	likely	





















Only	 around	 one‐quarter	 of	 women	 experiencing	 perinatal	 loss	
reported	 feeling	 anxious	 or	 distressed	 at	 discharge,	 which	 is	 lower	
than	other	estimates.22	The	EQ‐5D	was	not	designed	for	this	purpose	











may	 not	 have	 been	 assessed	 carefully	 for	 heart	 rate	 or	 resuscitated	
quickly.	There	are	limitations,	for	example,	confounders	to	some	of	the	
associations	were	not	included	in	the	data	collection,	such	as	maternal	










Mother’s problems with QoL overall Mother’s anxiety or depression
n (%)
Crude OR (95% CI) χ2 
test, P value
Adjusted ORb  (95% CI) 
LRT, P value n (%)
Crude OR (95% CI) 
χ2 test, P value
Adjusted ORb  (95% 
CI) LRT, P value
At	birth P<0.0001	(n=18 485) P<0.0001	(n=18 478) P<0.0001	(n=18 485) P<0.0001	(n=18 478)
Live	birth 6091	(36.53) 1.00 1.00 1383	(8.29) 1.00 1.00
Stillbirth 921	(50.91) 1.80	(1.63–1.99) 2.60	(2.30–2.95) 564	(28.19) 4.34	(3.86–4.89) 5.56	(4.83–6.41)
Pre‐discharge P<0.0001	(n=16 676) P<0.0001	(n=16 669) P<0.0001	(n=16 676) P<0.0001	(n=16 669)
Alive	at	
discharge
5968	(36.32) 1.00 1.00 1316	(8.01) 1.00 1.00
Neonatal	
death








































than	2000	deaths	were	 recorded	and	not	 reported	 in	 the	original	
reporting	of	this	trial,	it	is	recommended	that	maternal	health	stud‐
ies	should	also	report	perinatal	outcomes.24	This	is	particularly	rel‐
evant	 for	 cost‐effectiveness	analyses,	 as	 including	 such	outcomes	
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